Literature DB >> 6937239

Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.

W Plunkett, V Hug, M J Keating, S Chubb.   

Abstract

A method for the detection and quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP), the active metabolite cells and leukemic cells of the peripheral blood from patients receiving ara-C therapy is described. ara-CTP is separated from normal cellular nucleotides by high-pressure liquid chromatography and is quantitated by its absorbance of ultraviolet light at 280 nm with a lower limit of sensitivity of 25 pmol/2 x 10(7) cell equivalents. During separate courses of continuous infusion of different therapeutic doses of ara-C, ara-CTP accumulated in the leukemic bone marrow cells of a patient with acute myelogenous leukemia in proportion to the dose of ara-C. Continuous infusion of ara-C (90 mg/sq m/day) resulted in plateau levels of ara-CPT in peripheral blast cells after 24 hr (115 pmol/1 x 10(7) cell equivalents). A priming dose of ara-C(125 to 250 mg/sq m) followed by a 1-hr infusion of an equal dose of ara-C to patients with acute myelogenous leukemia facilitated the determination of ara-CTP retention in bone marrow and peripheral blood leukemic cells in vivo. This procedure should be useful for extended studies of the biochemical pharmacology of ara-CTP in vivo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6937239

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.

Authors:  Kumudha Balakrishnan; Christine M Stellrecht; Davide Genini; Mary Ayres; William G Wierda; Michael J Keating; Lorenzo M Leoni; Varsha Gandhi
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

2.  Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Kumudha Balakrishnan; Ramadevi Nimmanapalli; Farhad Ravandi; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

3.  A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

Authors:  Varsha Gandhi; John M Kilpatrick; William Plunkett; Mary Ayres; Leigh Harman; Min Du; Shanta Bantia; Jan Davisson; William G Wierda; Stefan Faderl; Hagop Kantarjian; Deborah Thomas
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

4.  Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Dushyant Verma; Susan O'Brien; John Michael Kilpatrick; Yuling Chen; Brenita F Tyler; Susan Bickel; Shanta Bantia; Michael J Keating; Hagop Kantarjian; Varsha Gandhi; Farhad Ravandi
Journal:  Blood       Date:  2010-04-28       Impact factor: 22.113

5.  Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.

Authors:  Ping Chen; Josephine Aimiuwu; Zhiliang Xie; Xiaohui Wei; Shujun Liu; Rebecca Klisovic; Guido Marcucci; Kenneth K Chan
Journal:  AAPS J       Date:  2010-12-30       Impact factor: 4.009

6.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

Authors:  Isam Abdel-Karim; William K Plunkett; Susan O'Brien; Francis Giles; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Min Du; Karen B Schneck; Victor J Chen; Boris K Lin; Steven J Nicol; Hagop M Kantarjian
Journal:  Invest New Drugs       Date:  2010-01-21       Impact factor: 3.850

8.  Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.

Authors:  V Heinemann; D Murray; R Walters; R E Meyn; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.

Authors:  V Gandhi; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Lisa S Chen; Sanjeev Redkar; David Bearss; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2009-09-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.